, and >20.0 ng/ml (n = 16 114), respectively. By contrast, the distribution of PCSM by PSA was linear for Gleason 7 (using PSA 4.1-10.0 ng/ml as the referent, n = 359 898), with an AHR of 0.41 (p = 0.13) for PSA 2.5 ng/ml (n = 37 812) versus 1.38, 2.28, and 4.61 for PSA of 2.6-4.0 (n = 54 152), 10.1-20.0 (n = 63 319), and >20.0 ng/ml (n = 35 459), respectively (p interaction < 0.001). Gleason 8-10, PSA 2.5 ng/ml disease had a significantly higher PCSM than standard high-risk/very highrisk disease with PSA >2.5 ng/ml (AHR 2.15, p = 0.002; 47-mo PCSM 14% vs 4.9%). Among
Prostate cancer is typically highly androgen-dependent and exquisitely sensitive to ADT [2] . In addition, PSA production is positively regulated by androgens [3] . Although PSA is typically elevated in high-grade disease, some patients present with the discordant scenario of high-grade disease and low PSA. The clinical and biological implications of low PSA in high-grade prostate cancer are unclear [4] . Low-PSA, high-grade disease may represent a unique entity with underlying dedifferentiated biology, and as such may respond poorly to current standard treatments, particularly ADT. However, there are few clinical and biological data to support this hypothesis [5] [6] [7] [8] .
The canonical low-PSA-producing prostate cancer is neuroendocrine prostate cancer, including the small-cell variant, which represents an aggressive and hormoneresistant entity [9] [10] [11] [12] . There is low sensitivity for the detection of neuroendocrine features on biopsy or RP specimens [9] . Emerging genomic characterization of neuroendocrine prostate cancer has identified common mutations that represent a "molecular signature" that may aid in detection and targeted therapy [12] [13] [14] [15] . Whether low-PSA, high-grade disease shares genomic features with neuroendocrine prostate cancer has not been explored.
Understanding the biology and behavior of low-PSA, highgrade prostate cancer is highly relevant; there is an active effort to improve the understanding and outcomes of aggressive localized prostate cancers through the utilization of genomics and application of targeted agents [16] [17] [18] [19] . Therefore, we characterized the prognostic and predictive values of low PSA in high-grade prostate cancer, as well as the genomic features of this entity among men diagnosed with prostate cancer.
2.
Patients and methods
Study cohorts

NCDB and SEER
The National Cancer Data Base (NCDB) captures 70% of incident cancers in the USA [20] and identified 494 793 patients diagnosed with SEER from 2010 onwards have been audited for accuracy [22] .
Therapy received included RP, radiotherapy (external beam radiotherapy [EBRT] or brachytherapy), and ADT (only available in the NCDB).
Gleason scores reflect pathologic grade when available or biopsy otherwise. Race was classified as Black or non-Black. The CharlsonDeyo comorbidity score was reported by the NCDB and was also used.
GRID
The 
Decipher GRID genomic analyses
We characterized the transcriptomic differences between tumors with PSA 2.5 and >2.5 ng/ml using 62 trained and validated prostate cancer expression signatures from GRID including signatures related to prognosis [23] , androgen receptor signaling [24] , and neuroendocrine/ small-cell disease (Supplementary material) [19] .
The Wilcoxon test was used to assess significant differences, and the Benjamini-Hochberg method was used for multiple testing adjustment.
Statistical tests
Statistical testing was two-sided with significance set at p = 0.025 after Bonferroni correction (n = 2 Gleason groups in prognostic analyses, n = 2 PSA groups in predictive analyses) and p = 0.050 for transcriptomic analysis after multiple testing correction. 
Results
Baseline characteristics
Baseline characteristics for the NCDB, SEER, and Decipher GRID cohorts are shown in Table 1 Table 2 ). Similarly, the distribution of ACM in the NCDB cohort was U-shaped with respect to PSA, with an AHR of 1.23 (95% CI 1.13-1.33; p < 0.001) for PSA ADT = androgen deprivation therapy; CDC = Charlson-Deyo comorbidity; IQR = interquartile range; PSA = prostate-specific antigen. a p < 0.001 for all characteristics comparing across all PSA groups. Percentages may not add to 100 due to rounding.
2.5 ng/ml versus 1.07, 1.30, and 1.50 for PSA 2.6-4.0, 10.1-20.0, and >20.0 ng/ml, respectively ( Supplementary Fig. 1A , Table 2 ).
By contrast, the PCSM distribution was linear for Gleason 7 disease, with an AHR of 0.41 (95% CI 0.13-1.29; p = 0.13) for PSA 2.5 ng/ml, versus 1.38, 2.28, and 4.61 for PSA 2.6-4.0, 10.1-20.0, and >20.0 ng/ml, respectively (Fig. 1B , Table 2 ). Similarly, the AHR for ACM was 1.03 (95% CI 0.99-1.08; p = 0.14) for PSA 2.5 ng/ml versus 0.83, 1.33, and 1.40 for PSA 2.6-4.0, 10.1-20.0, and >20.0 ng/ml, respectively ( Supplementary Fig. 1B , Table 2 ).
Significant interactions between PSA level and Gleason score were noted for both PCSM and ACM (both Gleason 8-10 disease with PSA 2.5 ng/ml had a higher risk of PCSM compared to NCCN high-risk/very high-risk disease with PSA >2.5 ng/ml (AHR 2.15, 95% CI 1.31-3.52; p = 0.002; 47-mo adjusted PCSM 14.0% vs 4.9%; Supplementary Table 3 , Fig. 1C) . Furthermore, Gleason 8-10 disease with PSA 2.5 ng/ml was associated with a higher risk of ACM compared to NCCN high-risk/very high-risk disease with PSA >2.5 ng/ml (AHR 1.15, 95% CI 1.07-1.25; p < 0.001; Supplementary Table 3, Supplementary Fig. 1C ). [ ( F i g . _ 1 ) T D $ F I G ] Furthermore, in patients treated with salvage ADT after RP, PSA 2.5 ng/ml was associated with the highest ACM for Gleason 8-10 tumors and the lowest ACM for Gleason 7 tumors (p interaction = 0.022; Supplementary Table 5 ; Supplementary Fig. 2A,B) .
3.4.
Genomic characteristics of low-PSA, high-grade tumors
We assessed differences in values for 62 prostate cancer transcriptomic signatures in the Decipher GRID, including signatures related to prognosis [23] , androgen receptor (AR) ACD = all-cause deaths; ACM = all-cause mortality; AHR = adjusted hazard ratio; CDC = Charlson-Deyo comorbidity; CI = confidence interval; N/A = not applicable; NCDB = National Cancer Data Base; PCD = prostate cancer deaths; PCSM = prostate cancer-specific mortality; PSA = prostate-specific antigen; SEER = Surveillance, Epidemiology and End Results. a Adjusted for receipt of androgen deprivation therapy for the NCDB cohort. signaling [24] , and neuroendocrine/small-cell prostate cancer [19] . After multiple testing adjustment, Gleason 8-10 tumors with PSA 2.5 ng/ml were more likely to be associated with neuroendocrine/small-cell genomic signatures and less likely to be associated with an AR signaling signature compared to Gleason 8-10 tumors with PSA >2.5 ng/ml (both p = 0.046; Fig. 3A,B ). No such relationship was seen for Gleason 7 tumors (Fig. 3C,D) .
[ ( F i g . _ 2 ) T D $ F I G ]
Discussion
In this large, contemporary study of patients from three national cohorts, we found that low-PSA, high-grade prostate cancer appears to be a unique and aggressive entity among men with prostate cancer, with poor clinical outcomes and genomic features of neuroendocrine dedifferentiation. Characterization of this disease as a unique entity distinguishable by expression profiling from other high-grade prostate adenocarcinomas has not been reported in the literature, and the implications of these findings are highly clinically significant. We demonstrated that low-PSA, high-grade disease is associated with a more than twofold higher risk of prostate cancer death relative to NCCN high-risk/very high-risk disease, with a large number of deaths occurring within a short interval after diagnosis. Whereas a low PSA is typically seen as portending a favorable prognosis in prostate cancer, our findings suggest that it actually portends a higher risk of PCSM in high-grade disease. In addition, ADT when combined with radiotherapy is known to improve survival in high-grade disease, but our findings suggest that this is actually not true when PSA is 2.5 ng/ml. Lastly, low-PSA, high-grade disease is associated with higher expression of markers for neuroendocrine/small-cell disease and lower AR signaling compared to other patients with high-grade disease, while no such difference was detected by PSA for low-grade disease. Lower expression of AR signaling and higher expression of neuroendocrine markers are associated with a neuroendocrine phenotype, which has a poorer response to hormonal therapy and poorer cancer outcome [19, 23, 24] . Thus, our clinical and genomic data strongly suggest that low-PSA, high-grade prostate cancer is a clinically and biologically unique entity that is associated with poor prognosis and that may not respond well to ADT. This study has two major clinical implications. First, our results suggest that modification may be needed for existing clinical prognostic tools for prostate cancer, which predict a linear relationship between PSA and prognosis [25] [26] [27] . We found that although there is a positive linear relationship between outcomes and PSA for Gleason 7 tumors as predicted by prognostic nomograms, these clinical nomograms are inaccurate for high-grade disease, for which the prognosis for low PSA appears to be as equally poor as for elevated PSA. Second, our findings suggest that the current paradigm for treating all high-risk localized disease using radiation and long-term ADT alone may need modification, as our study suggests that low-PSA, high-grade tumors may respond poorly to ADT. The poor prognosis and potentially lower ADT response of low-PSA, high-grade cancer distinguish it from conventional prostate adenocarcinoma, and our expression data provide biological evidence of these clinical observations.
It has been hypothesized that low-PSA, high-grade prostate cancer reflects dedifferentiated, clinically aggressive, and hormone-resistant tumors, but until now the evidence has been limited [5] [6] [7] [8] . By demonstrating that low-PSA, high-grade tumors may be potentially resistant to ADT and possess neuroendocrine genomic features, our results provide the first clinical and biological validation of this longstanding hypothesis. Furthermore, these findings also highlight the potential difficulties with detecting this unique aggressive entity, which would not necessarily be diagnosed through PSA screening as the PSA levels would typically be below the threshold to biopsy. Thus, it is likely that such patients with aggressive cancers could be diagnosed based on some combination of digital rectal examination, clinical symptom presentation, and PSA kinetics. Whether there are low-PSA, high-grade tumors that remain latent is unknown, since patients who are discovered to have high-grade disease would be treated as high risk.
Given the poor prognosis and unique characteristics of this disease, there is an urgent need for further molecular, genomic, and clinical characterization as well as clinical trials involving chemotherapy and/or novel targeted agents. We propose movement towards the utilization of new prognostic tools and treatment paradigms in this setting. Genomic signature testing may aid in both identifying neuroendocrine biology that is difficult to capture morphologically and in predicting the prognosis of low PSA in highgrade disease, which current nomograms and clinical testing cannot do accurately. Since low-PSA, high-grade disease tends to be late-presenting given that low PSA does not typically prompt a biopsy, the development of additional biomarkers to aid in early detection of aggressive and poorly differentiated disease is necessary. Furthermore, whether low-PSA, high-grade tumors are a heterogeneous entity with a mixture of tumor types such as aggressive neuroendocrine and more standard-risk prostate adenocarcinoma would need to be determined in developing new approaches to this disease.
In moving towards a new treatment paradigm, one hypothesis is that patients with low-PSA, high-grade disease may be the group that would benefit the most from addition of chemotherapy to standard hormonal therapy for high-risk localized disease, on the basis of new randomized evidence showing the benefit of chemotherapy in localized high-risk disease [16, 28] . Furthermore, this group may benefit from early addition of chemotherapy should further studies confirm ADT resistance in these patients. While docetaxel has been favored as the chemotherapy of choice for high-risk localized disease, a platinum-based agent could also be considered in the setting of a clinical trial given the neuroendocrine expression features of low-PSA, high-grade tumors [1] . It has been demonstrated that neuroendocrine prostate cancer has significant overexpression and amplification of specific markers, and there are ongoing phase 2 studies evaluating the efficacy of targeted inhibition in the metastatic setting (NCT01799278). Depending on the results of this study, the expansion of targeted inhibition for patients with low-PSA, high-grade disease in an investigative setting may be appropriate. Furthermore, there is a rationale to hypothesize that surgery, either upfront or in combination with radiation and/or systemic therapy, may be a more appropriate initial strategy for this group, given that the disease may be less responsive to ADT. Ultimately, our findings will need to be prospectively validated before we would recommend changes to initial management approaches, although clinicians should proceed with caution and consider aggressive management as clinically indicated. Lastly, it should be noted that an alternative surveillance strategy to PSA monitoring that involves imaging may be needed given that these tumors produce little PSA.
Our findings must be viewed within the inherent limitations of a database analysis. First, SEER does not contain information on ADT or comorbidity status. To account for this limitation, we used the NCDB, which has robust information on these data. Second, the NCDB does not contain information on cause of death. To address this limitation, we used SEER, which contains information on cause of death. Third, it is unknown how many patients were potentially captured by both SEER and NCDB, as such information is unavailable, although we would consider this to be a minor inherent limitation of using both databases balanced against the significant benefit of addressing the limitations of each database by using both. Fourth, the number of patients included in the genomic analyses was smaller than the number for clinical analyses. Nevertheless, there was enough power to detect a significant difference in genomic expression based on PSA among high-Gleason tumors. Fifth, given that chemotherapy was not considered the standard of care during the study period, only 1393 patients in our cohort received chemotherapy (including only 60 patients with low-PSA, high-grade disease), making our study underpowered to assess response to chemotherapy. Lastly, the follow-up periods for our clinical cohorts were relatively short, but the aggressive nature of low-PSA, highgrade disease allowed us to detect a difference in survival within these short follow-up periods.
Conclusions
In summary, low-PSA, high-grade prostate cancer appears to be a unique entity among men with prostate cancer that has very high risk for prostate cancer death, potentially responds poorly to ADT, and is more likely to be associated with neuroendocrine genomic features. Clinicians, researchers, and patients need to be aware of the potentially worse oncologic outcomes associated with this newly characterized disease. We recommend a concerted effort from the prostate cancer research community to guide the development of prognostic tools, novel therapeutics, and clinical management for low-PSA, high-grade prostate cancer.
Author contributions: Paul L. Nguyen had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: Mahal, Yang, Feng, Nguyen.
Acquisition of data: Mahal, Wang, Alshalalfa, Davicioni, Choeurng, Schaeffer, Ross, Spratt, Den, Martin, Orio, Trinh, Feng, Nguyen.
Analysis and interpretation of data: All authors.
Drafting of the manuscript: Mahal, Yang, Feng, Nguyen.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Mahal, Yang, Wang, Alshalalfa, Davicioni, Choeurng.
Obtaining funding: Nguyen.
Administrative, technical, or material support: Mahal, Yang, Wang, Alshalalfa, Davicioni, Choeurng.
Supervision: Feng, Nguyen.
Other: None. Ventre Fund, and a grant from an anonymous family foundation. The sponsors played no direct role in the study.
